WO2025229623 - ENGINEERED CYTOKINES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/229623
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054644
International Filing Date
02.05.2025
Title **
[English]
ENGINEERED CYTOKINES AND USES THEREOF
[French]
CYTOKINES MODIFIÉES ET LEURS UTILISATIONS
Applicants **
PEPTONE, LTD.
Inventors
HENDERSON, Louie
DUTTON, Oliver
HOFFMAN, Falk
BOTTARO, Sandro
REDL, Istvan
FISICARO, Carlo
OWENS, Benjamin
KUNZ, Patrick
LAKINS, Matthew
FOERCH, Patrik
LOWE, David
TAMIOLA, Kamil
Priority Data
63/642,323
03.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5776 | |
| EPO | Filing, Examination, Granting | 124308 | |
| Japan | Filing, Examination, Granting | 5016 | |
| South Korea | Filing, Examination, Granting | 8348 | |
| USA | Filing, Examination, Granting | 38590 |
Total:
182,038
Abstract[English]
Disclosed herein are engineered cytokines fused to a second polypeptide, such as an antigen binding polypeptide, and compositions and uses thereof, and in silico methods for the engineering cytokines generated from artificial neural network machine learning protocols and/or molecular dynamics simulations. Also disclosed herein are polypeptide structures designed using AI methods with modulated stability, potency and developability. Also disclosed herein are compositions containing engineered cytokines fused to a second polypeptide, such as an antigen binding polypeptide, for pharmaceutical use, as well as methods of treating a subject by administering to the subject compositions containing the same.[French]
L'invention concerne des cytokines modifiées fusionnées à un second polypeptide, tel qu'un polypeptide de liaison à l'antigène, et des compositions et leurs utilisations, et des méthodes in silico pour les cytokines modifiées générées à partir de protocoles d'apprentissage automatique de réseau neuronal artificiel et/ou de simulations de dynamique moléculaire. Il est également divulgué des structures polypeptidiques conçues à l'aide de méthodes IA ayant une stabilité, une puissance et une aptitude au développement modulées. L'invention concerne également des compositions contenant des cytokines modifiées fusionnées à un second polypeptide, tel qu'un polypeptide de liaison à l'antigène, pour une utilisation pharmaceutique, ainsi que des méthodes de traitement d'un sujet par administration au sujet de compositions les contenant.